{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:27:18Z","timestamp":1792207638928,"version":"4.4.0"},"reference-count":13,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,2,10]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r\/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is a life-threatening treatment-related toxicity that limits the full therapeutic potential in adults. We report outcomes for adults with r\/r ALL treated with an optimized CTL019 dosing and CRS management strategy. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> Adults with r\/r B-cell ALL received CTL019 in 1 of 2 trials. Patients received lymphodepletion followed by CTL019 as either a one-time infusion or fractionated infusions split over 3 days (day 1, 10%; day 2, 30%; day 3, 60%), which allowed for day 2 and day 3 doses to be held for early CRS. Total planned CTL019 dose varied with adaptive protocol modifications in response to efficacy and CRS toxicity. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Thirty-five adults with r\/r ALL received CTL019 in 1 of 3 dosing cohorts. The low-dose cohort (n = 9) received single or fractionated dosing and had manageable toxicity with a 33% complete remission (CR) rate. In the high-dose single infusion cohort, 3 of 6 patients with refractory CRS concurrent with culture-positive sepsis died, and 3 achieved CR. The 20 patients in the high-dose fractionated (HDF) cohort had a 90% CR rate and manageable CRS. The HDF cohort had the highest survival, with a 2-year overall survival of 73% (95% CI, 46% to 88%) and event-free survival of 49.5% (95% CI, 21% to 73%). <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> Fractionated dosing of CTL019 with intrapatient dose modification optimizes safety without compromising efficacy in adults with r\/r ALL. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.19.01892","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T21:02:07Z","timestamp":1575925327000},"page":"415-422","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":242,"title":["Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia"],"prefix":"10.1200","volume":"38","author":[{"given":"Noelle V.","family":"Frey","sequence":"first","affiliation":[{"name":"Division of Hematology Oncology, Abramson Cancer Center, Cell Therapy and Transplant, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela A.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Abramson Cancer Center, Cell Therapy and Transplant, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Pequignot","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar","family":"Gill","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Abramson Cancer Center, Cell Therapy and Transplant, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Abramson Cancer Center, Cell Therapy and Transplant, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Mangan","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Abramson Cancer Center, Cell Therapy and Transplant, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Abramson Cancer Center, Cell Therapy and Transplant, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Abramson Cancer Center, Cell Therapy and Transplant, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Maude","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Gilmore","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapy, University of Pennsylvania Perlman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"Lacey","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapy, University of Pennsylvania Perlman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos J.","family":"Melenhorst","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapy, University of Pennsylvania Perlman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapy, University of Pennsylvania Perlman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Center for Cellular Immunotherapy, University of Pennsylvania Perlman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Abramson Cancer Center, Cell Therapy and Transplant, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.567"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.11.710"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7019"},{"key":"B15","unstructured":"Van Belle G. Statistical Rules of Thumb. Hoboken, NJ, Wiley, 2011"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.19.01892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:06:44Z","timestamp":1653811604000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.01892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,2,10]]}},"alternative-id":["10.1200\/JCO.19.01892"],"URL":"https:\/\/doi.org\/10.1200\/jco.19.01892","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"2019-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}